Syndax Pharmaceuticals is looking to raise $69 million in an IPO, planning to move 4.3 million shares at between $13 and $15 apiece. The Waltham, MA, biotech disclosed its terms in a Thursday filing, planning to trade on the Nasdaq under "SNDX" and spend its proceeds on entinostat, a Phase III oncology treatment that received the FDA's coveted breakthrough-therapy designation last year. The drug is an oral histone deacetylase inhibitor designed to work in tandem with hormone therapy to treat metastatic, HR-positive breast cancer. S-1